Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Google AI System Beats Doctors in Detecting Breast Cancer

By HospiMedica International staff writers
Posted on 06 Jan 2020
A team of researchers from Google Health (Palo Alto, CA, USA) have developed an artificial intelligence (AI) model which can spot breast cancer in de-identified screening mammograms (where identifiable information has been removed) with greater accuracy, fewer false positives, and fewer false negatives than experts. More...
This can find future applications wherein the model could support radiologists performing breast cancer screenings.

Despite the wide use of digital mammography, or X-ray imaging of the breast, to screen for breast cancer, spotting and diagnosing the disease early remains a challenge even for experts, and can often result in both false positives and false negatives. Such inaccuracies can lead to delays in detection and treatment, unnecessary stress for patients and a higher workload for radiologists who are already in short supply.

Over the last two years, Google Health has been working with leading clinical research partners in the UK and US to see if AI can improve the detection of breast cancer by supporting radiologists to spot the signs of breast cancer more accurately. The researchers trained and tuned the AI model on a representative data set comprised of de-identified mammograms from more than 76,000 women in the UK and 15,000 women in the US to see if it could learn to spot signs of breast cancer in the scans. They went on to evaluate the model on a separate de-identified data set of more than 25,000 women in the UK and 3,000 women in the US In this evaluation, the model produced a 5.7% reduction of false positives in the US and a 1.2% reduction in the UK. It produced a 9.4% reduction in false negatives in the US and a 2.7% reduction in the UK.

In order to see if their model could generalize to other healthcare systems, the researchers trained it only on the data from the women in the UK and then evaluated it on the data set from women in the US. In this separate experiment, there was a 3.5% reduction in false positives and an 8.1% reduction in false negatives, indicating the model’s potential to generalize to new clinical settings while still performing at a higher level than experts. Despite the model only processing the most recent anonymized mammogram and receiving less information than human experts who had access to patient histories and prior mammograms, it surpassed individual experts in accurately identifying breast cancer.

Related Links:
Google Health


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical Examination & Procedure Light
Vega 80
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Critical Care

view channel
Image Credit: 123RF

AI-Enhanced Handheld Ultrasound Improves Carotid Plaque Detection

Handheld ultrasound can miss small or faint carotid plaque, creating uncertainty in community screening. This gap makes it harder for frontline clinicians to decide who needs confirmatory imaging, closer... Read more

Surgical Techniques

view channel
Image: Associate Professor Menglin Chen studies how the light-sensitive nanoparticles affect living cells. The screen shows calcium being released inside a cell after nanoparticles taken up by the cell are exposed to blue light. Calcium plays an important role in cellular signaling, and the experiment helps the researchers understand how the nanoparticles can translate light into biological activity. (Photo courtesy of Aarhus University, Johanne Holm Jensen)

Light-Activated Nanoparticles May Offer New Approach to Retinal Prostheses

Retinitis pigmentosa is a degenerative retinal disorder in which photoreceptors progressively die, reducing visual signals to the brain while leaving surviving inner retinal circuits underused.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.